Send the following on WhatsApp
Continue to ChatI liked this article on M3 India: Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Have a read: https://www.m3india.in/contents/journal/four-year-follow-up-of-a-single-arm-phase-ii?utm_campaign=unset&utm_medium=share&utm_source=ref_wa